December 3, 2018What's New
Target Health is very active in the Orphan Drug space with an ongoing global Phase 3 program in a rare disease. Other programs include a rare epilepsy in children and a rare skin disease. We also obtained multiple FDA and EMA Orphan Drug Designations for our clients, and actively involved with the development of several products that are now being marketed.
Our friend and colleague Professor Ari Zimran, MD, Director of the Gaucher Clinic at Shaare Zedek Medical Center in Jerusalem, Israel, is chairing the RARE2019 conference, taking place on June 13-14, at the Hilton East Brunswick Hotel & Executive Meeting Center in New Brunswick, NJ. Block in the date and we will share more information as it becomes available. Dr. Jules Mitchel, President of Target Health will be presenting on Study designs for rare diseases.
For our European friends, the 2nd International Congress on Advanced Treatments in Rare Diseases (RARE2019), will take place on 4-5 March 2019 in Vienna, Austria.
For more information about Target Health, contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors.
Joyce Hays, Founder and Editor in Chief of On Target
Jules Mitchel, Editor